Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 13 Issue 3, March 2014

In This Issue

Top of page ⤴

Comment

  • Recent policy developments in the European Union and elsewhere aim to tackle some of the key issues responsible for the limited adoption of personalized medicine approaches so far.

    • Charity Nofziger
    • Marisa Papaluca
    • Markus Paulmichl
    Comment
Top of page ⤴

News and Analysis

  • A new model of company creation pioneered by Lilly, Celgene, Sanofi, Roche and others is set to deliver both clinical candidates and platform technologies.

    • Asher Mullard
    News and Analysis
  • Chronic lymphocytic leukaemia (CLL) has become a fertile testing ground for novel targeted agents, one of which may become the most lucrative haematology drug in history.

    • Ken Garber
    News and Analysis
Top of page ⤴

News in Brief

Top of page ⤴

Biobusiness Briefs

Top of page ⤴

Patent Watch

Top of page ⤴

An Audience With

  • John Reed, Head of Pharma Research & Early Development at Roche, discusses his plans to tweak the therapeutic focus, clinical development strategy and externalization of innovation at Roche.

    An Audience With
Top of page ⤴

From the Analyst's Couch

  • The late-stage pipeline for systemic lupus erythematosus (SLE) and lupus nephritis (LN) contains biologics and small-molecule drugs for a broad range of different targets. Koutsokeras and Healy discuss their likely impact on the future SLE and LN market.

    • Toli Koutsokeras
    • Tina Healy
    From the Analyst's Couch
Top of page ⤴

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Opinion

  • Agents that target tumour-supportive cellular machineries, such as the proteasome, heat shock protein complexes and proteins involved in chromatin modifications, are emerging as a new wave of anticancer drugs. Here, Dobbelstein and Moll provide their perspective on the advantages and limitations of these agents compared with established drugs that target DNA replication or signalling proteins such as kinases.

    • Matthias Dobbelstein
    • Ute Moll
    Opinion
Top of page ⤴

Review Article

  • This Review highlights recent progress in the development of ligands to target two classes of nuclear receptors — the REV-ERBs and retinoic acid receptor-related orphan receptors (RORs) — and describes how such ligands might be useful for treating disorders related to metabolism, immune function and the circadian rhythm.

    • Douglas J. Kojetin
    • Thomas P. Burris
    Review Article
  • The tumour suppressor p53 is the most frequently mutated gene in human cancer, and drugs that restore or activate the p53 pathway have now reached clinical trials. Most of these drugs inhibit MDM2, a negative regulator of p53. In this Review, Lane and colleagues provide an overview of the different therapeutic approaches to targeting the p53 pathway and discuss the state of development of p53 pathway modulators.

    • Kian Hoe Khoo
    • Chandra S. Verma
    • David P. Lane
    Review Article
Top of page ⤴

Search

Quick links